NCT04294290View on ClinicalTrials.gov

Open Label Phase I hCT-MSC in Toddlers With Autism Spectrum Disorder

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 24, 2021

Primary Completion Date

August 17, 2022

Study Completion Date

August 17, 2022

Conditions
Autism Spectrum Disorder
Interventions
BIOLOGICAL

hCT-MSC infusion

This is a single site, phase I, open-label, prospective study of one intravenous infusion of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) in 12 toddlers 18 to 48 months of age with autism spectrum disorder (ASD).

Trial Locations (1)

27705

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

The Marcus Foundation

OTHER

lead

Duke University

OTHER

NCT04294290 - Open Label Phase I hCT-MSC in Toddlers With Autism Spectrum Disorder | Biotech Hunter | Biotech Hunter